When used in conjunction with chemotherapy, the BsAb zanidatamab, which targets two distinct HER2 epitopes, was well-tolerated and had anti-tumor effectiveness in BC patients with metastatic HER2-amplified disease [249]. Here, ERBB2 is linked to neoplasm.